Literature DB >> 21991171

Stevens-johnson syndrome: a case report.

O Castana1, G Rempelos, G Anagiotos, C Apostolopoulou, A Dimitrouli, D Alexakis.   

Abstract

The Stevens-Johnson syndrome has the appearance of a partial-thickness burn that may lead to a 100% loss of epidermis, requiring the same resuscitation as a severe burn. A 38-yr-old male patient was admitted to the neurosurgery department of the Evangelismos General Hospital in Athens, where immediately after administration of an antiepileptic drug he developed sloughing of total epidermis, high fever, and the clinical picture of a severe burn patient. He was treated as a burn patient with massive cutaneous injuries and the concomitant systemic effects. Fluid resuscitation was important and the Parkland formula was used, as in a burn patient. Steroid medications were initially administered. Systemic antibiotics were discontinued after signs of sepsis and documented infection had been overcome. Improved treatment techniques and critical burn care have decreased mortality and morbidity in cases of the Stevens-Johnson syndrome. Prompt recognition of the disease and cure of the patient by the appropriate staff of the burns centre contribute to the successful treatment of such patients.

Entities:  

Keywords:  CASE REPORT; STEVENS-JOHNSON; SYNDROME

Year:  2009        PMID: 21991171      PMCID: PMC3188138     

Source DB:  PubMed          Journal:  Ann Burns Fire Disasters        ISSN: 1592-9558


  6 in total

1.  Medical genetics: a marker for Stevens-Johnson syndrome.

Authors:  Wen-Hung Chung; Shuen-Iu Hung; Hong-Shang Hong; Mo-Song Hsih; Li-Cheng Yang; Hsin-Chun Ho; Jer-Yuarn Wu; Yuan-Tsong Chen
Journal:  Nature       Date:  2004-04-01       Impact factor: 49.962

2.  Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions.

Authors:  B Rzany; O Correia; J P Kelly; L Naldi; A Auquier; R Stern
Journal:  Lancet       Date:  1999-06-26       Impact factor: 79.321

Review 3.  The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification.

Authors:  J C Roujeau
Journal:  J Invest Dermatol       Date:  1994-06       Impact factor: 8.551

4.  Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study.

Authors:  Ariane Auquier-Dunant; Maja Mockenhaupt; Luigi Naldi; Osvaldo Correia; Werner Schröder; Jean-Claude Roujeau
Journal:  Arch Dermatol       Date:  2002-08

5.  Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.

Authors:  J C Roujeau; J P Kelly; L Naldi; B Rzany; R S Stern; T Anderson; A Auquier; S Bastuji-Garin; O Correia; F Locati
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

6.  Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.

Authors:  S Bastuji-Garin; B Rzany; R S Stern; N H Shear; L Naldi; J C Roujeau
Journal:  Arch Dermatol       Date:  1993-01
  6 in total
  4 in total

1.  Phenytoin induced Stevens-Johnson syndrome exacerbated by cefepime.

Authors:  Varsha A Prabhu; Sahiti Doddapaneni; Girish Thunga; Rajakannan Thiyagu; M Mukyaprana Prabhu; Kushal Naha
Journal:  J Pharmacol Pharmacother       Date:  2013-10

2.  Stevens-Johnson syndrome caused by cefepime?

Authors:  Luciano Mavilia; Mavilia Luciano; Caterina Trifirò; Trifiro' Caterina; Santo Raffaele Mercuri; Mercuri Santo Raffaele
Journal:  J Pharmacol Pharmacother       Date:  2015 Jan-Mar

3.  Diagnosis and treatment of flurbiprofen-induced Stevens-Johnson syndrome: A rare case report.

Authors:  Asad Ali Khan; Farhana Rashid; Farhat Ullah Khan; Tahmina Tahmina; Said Amin; Ayush Anand
Journal:  Clin Case Rep       Date:  2022-09-23

4.  Daunorubicin induced Stevens-Johnson syndrome: A case report.

Authors:  Preeti Shakya; Amit Sharma Nepal
Journal:  Clin Case Rep       Date:  2021-07-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.